Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Rating)’s share price was up 8.5% during trading on Monday . The company traded as high as $2.24 and last traded at $2.16. Approximately 125,607 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 970,433 shares. The stock had previously closed at $1.99.
Analyst Ratings Changes
A number of equities research analysts have commented on LYEL shares. HC Wainwright reduced their price objective on Lyell Immunopharma from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, March 2nd. Morgan Stanley reduced their price objective on Lyell Immunopharma from $7.00 to $4.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 24th.
Lyell Immunopharma Price Performance
The stock has a fifty day moving average price of $2.80 and a two-hundred day moving average price of $4.56. The company has a market cap of $586.58 million, a P/E ratio of -3.18 and a beta of -1.68.
Institutional Trading of Lyell Immunopharma
Hedge funds have recently bought and sold shares of the business. E Fund Management Co. Ltd. bought a new stake in Lyell Immunopharma during the third quarter worth $104,000. Massachusetts Financial Services Co. MA lifted its holdings in Lyell Immunopharma by 7.3% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,059,897 shares of the company’s stock worth $7,769,000 after acquiring an additional 71,788 shares during the period. New York State Common Retirement Fund lifted its holdings in Lyell Immunopharma by 7.3% during the third quarter. New York State Common Retirement Fund now owns 117,792 shares of the company’s stock worth $863,000 after acquiring an additional 8,050 shares during the period. Barclays PLC lifted its holdings in Lyell Immunopharma by 1,451.2% during the third quarter. Barclays PLC now owns 134,708 shares of the company’s stock worth $988,000 after acquiring an additional 126,024 shares during the period. Finally, Camden Capital LLC bought a new stake in Lyell Immunopharma during the third quarter worth $110,000. 45.04% of the stock is currently owned by institutional investors.
Lyell Immunopharma Company Profile
Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.
- Get a free copy of the StockNews.com research report on Lyell Immunopharma (LYEL)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.